United Therapeutics (UTHR) Tops Q3 EPS by 82c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $608.13 +1.13%
Financial Fact:
Income from continuing operations before income taxes: 239.1M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Income from continuing operations before income taxes: 239.1M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q3 EPS of $4.69, $0.82 better than the analyst estimate of $3.87. Revenue for the quarter came in at $446 million versus the consensus estimate of $426.43 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfspeed (WOLF) Misses Q1 EPS by 147c; Offers Guidance
- Klaviyo, Inc. (KVYO) Tops Q3 EPS by 26c, Beats on Revenue; Offers FY26 Revenue Guidance
- TKO Group Holdings (TKO) Tops Q3 EPS by 11c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
